mergers & acquisitions

With its purchase of decision support technology maker Interactive Biosoftware, Sophia looks to extend its AI platform deeper into NGS interpretation.

The merger, which was previously scuttled and later revived with Rosetta shareholder approval, was due to close on May 27.

The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.

Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.

In a note to investors, Cowen analyst Doug Schenkel called the decision "odd," and wondered if there would be more to come.

The company said its product revenues for the year rose 101 percent while its services revenues rose 7 percent.

TGR's proprietary protein capturing technology is expected to complement Sygnis' range of immunology, genomic, and proteomic products and services.

Agilent said the acquisition will enable it to provide consumers with a single informatics solution across laboratory and operational domains.

The offer put a value of 181 pence per share on Horizon's stock, representing a premium of approximately 26 percent to Horizon's closing share price on May 1.

The deal marks the latest in a series of acquisition LGC has made in recent years to expand its presence on the nucleic acid chemistry market.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.